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Background: Accumulating evidence suggests that growth hormone (GH) may play a major role in the regulation
of postnatal neurogenesis, thus supporting the possibility that it may be also involved in promoting brain repair
after brain injury. In order to gain further insight on this possibility, in this study we have investigated the
pathways signaling the effect of GH treatment on the proliferation and survival of hippocampal subgranular zone
(SGZ)-derived neurospheres.
Results: Our results demonstrate that GH treatment promotes both proliferation and survival of SGZ neurospheres.
By using specific chemical inhibitors we have been also able to demonstrate that GH treatment promotes the
activation of both Akt-mTOR and JNK signaling pathways, while blockade of these pathways either reduces or
abolishes the GH effects. In contrast, no effect of GH on the activation of the Ras-ERK pathway was observed
after GH treatment, despite blockade of this signaling path also resulted in a significant reduction of GH effects.
Interestingly, SGZ cells were also capable of producing GH, and blockade of endogenous GH also resulted in a
decrease in the proliferation and survival of SGZ neurospheres.
Conclusions: Altogether, our findings suggest that GH treatment may promote the proliferation and survival of
neural progenitors. This effect may be elicited by cooperating with locally-produced GH in order to increase the
response of neural progenitors to adequate stimuli. On this view, the possibility of using GH treatment to promote
neurogenesis and cell survival in some acquired neural injuries may be envisaged.
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Since the discovery of newly generated neurons in the
fully developed mammalian brain [1], research on adult
neurogenesis has become one of the major goals of neuro-
science. Under unperturbed conditions, postnatal neuro-
genesis is particularly important in two well-defined
anatomical regions of the central nervous system (CNS):
the subventricular zone (SVZ) lining the lateral walls of
the anterior lateral ventricles; and the subgranular zone
(SGZ) of the dentate gyrus (DG) of the hippocampus
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unless otherwise stated.neurogenic niches continuously self-renew and differenti-
ate into multiple neural lineages, thus allowing the equi-
librium between cell loss and cell replacement while
maintaining the NSC pool [6]. In addition, accumulating
evidence indicates that increased postnatal neurogenesis
may be also observed in response to acute injury to the
CNS, thus suggesting that new neurons may be generated
in order to replace those lost owing to tissue wound and
therefore contribute to the healing [7-11].
However, regardless of the time elapsed since the first dis-
covery of postnatal mammalian neurogenesis, key informa-
tion is still lacking about the regulatory mechanisms
controlling the self-renewal and differentiation processes
[12]. Postnatal neurogenesis has been shown to be regulated
by a number of extrinsic factors such as pharmacologicalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 GH and GHR expression in SGZ-derived neurospheres.
A) Evolution of neurosphere size after 7 (left), 12 (middle) or 15
(right) days in culture. B) Evolution of neurosphere number after
7-9 (left) or 13-15 (right) days in culture. In both cases, neurospheres
were cultured in DMEM containing 1% Gibco B27 supplement, EGF
(10 ng/mL) and FGF2 (10 ng/mL). C to E) SGZ-derived neurospheres
express GHR and GH. Neurospheres were cultured for 7 days in
DMEM containing 1% Gibco B27 supplement, and GH, GHR, GFAP
and nestin immunoreactivities were detected with specific antibodies.
GHR immunoreactivity is shown in red (C, D). GH immunoreactivity
is shown in red (E). GFAP immunoreactivity is shown in green
(C, E). Nestin immunoreactivity is shown in green (D). Scale bar = 10 μm.
Table 1 Evolution of neurosphere size and number
A) Days 7 12 15
Neurosphere size (mm) 23.1 ± 0.8 32.3 ± 0.9* 35.1 ± 1.5*
B) Days 7-9 13-15
Neurosphere number 139.4 ± 6.4 331.2 ± 10.0º
Cells were grown in defined media as described for the indicated times. * = p< 0.01
vs day 7; ° = p< 0.01 vs day 7-9.
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[2,13,14]. In addition, postnatal neurogenesis is regu-
lated by numerous hormones, among which the growth
hormone (GH)-insulin-like growth factor-1 (IGF1) system
seems to play a pivotal role [15]. The existence of important
neurogenic (and neurotrophic) actions of GH in the adult
brain has been demonstrated both in humans and labora-
tory animals [16-21]. Furthermore, GH has been shown to
potentiate the neurogenesis induced in response to brain
injury [22-24], thus leading to the possibility of using the
hormone in the treatment of some neural diseases. How-
ever, little is known about the mechanisms underlying the
neurogenic actions of GH, although they may depend, at
least in part, on the stimulation of the proliferation, differ-
entiation and survival of neural precursors. Therefore, this
study was designed to investigate to role of GH in the regu-
lation of the proliferation and survival of cultured neuro-
spheres obtained from the DG of postnatal mice, as well as
the molecular mechanisms underlying those effects.
Results
Establishment and characterization of SGZ-derived neuro-
sphere cultures
SGZ-derived neurospheres obtained from neonatal
(9 day old) mice were able to grow and give rise to new
neurospheres upon passaging, thus demonstrating their
capacity of self-renewal (Figures 1A and B, see also Table 1).
In addition, these neurospheres were able to generate ei-
ther GFAP- nestin- or O4-positive cells upon differenti-
ation (data not shown). By using a polyclonal anti-GHR
antibody we found the presence of GHR immunoreactivity
in cells co-expressing either Nestin (Figure 1C) or GFAP
(Figure 1D). In contrast, we have been unable to find GHR
immunoreactivity in O4-positive cells (data not shown).
GH immunoreactivity was also observed in neurosphere
cells co-expressing GFAP (Figure 1D).
GH treatment promotes the proliferation and survival of
SGZ-derived neurospheres
Treatment of SGZ-derived neurospheres with GH resulted
in a significant increase in the amount of BrdU incorpor-
ation (Figures 2A and B); an effect that was prevented by
treating the cells with the GHR antagonist pegvisomant.
Since pegvisomant hinders the binding of GH to its recep-
tor, this finding demonstrates that GH-induced prolifera-
tion depends on stimulation of GHR. Interestingly, a
significant decline in the proliferation of neurosphere cul-
tures was also observed when pegvisomant was given
alone (i.e. in the absence of exogenous GH) (Figures 2A
and B). In contrast with these findings, GH was ineffective
in promoting neurosphere proliferation when was given in
the absence of EGF and FGF (Figure 2C).
In addition to promote proliferation, GH treatment was
able to significantly reduce the apoptosis in neurospherecultures (Figure 3). In order to induce cell death, neuro-
sphere cultures were placed in media devoid of EGF and
FGF. Under these experimental conditions, the number of
apoptotic cells significantly increased with regard to cells
growing in defined media (Figure 3), but this was counter-
acted by treating the cells with GH (Figure 3). Also in this
case, the GH effect was prevented by treating the cells
with pegvisomant, thus demonstrating the involvement of
GHR. In concordance with the effect of pegvisomant on
cell proliferation, a significant increase in apoptotic cell
death was also observed when pegvisomant was given
alone (Figure 3).
Role of the Ras-ERK signaling pathway in the proliferative
and antiapoptotic effects of GH
The importance of ERK phosphorylation in transducing
GH actions has been previously demonstrated in different
cell types [25,26]. Therefore, in order to investigate the
Figure 2 GH treatment promotes the proliferation of SGZ neurospheres. A) Neurospheres growing in defined media were treated for 24 h
with GH (500 ng/mL), pegvisomant (Peg, 20 μg/mL), or GH + pegvisomant. Control cells were treated with saline. Four hours before the end
of the treatment period cells were given a BrdU pulse (10 μM). Neurospheres were then dissociated, cells were collected by centrifugation
onto coated cover slips, and BrdU was detected by immunocytochemistry. Each bar represents the mean + SEM of 3 experiments in triplicate.
* = p < 0.05 vs Control; ° = p <0.05 vs Control and GH. B) Representative images of results presented in A. Scale bar = 10 μm. C) Neurospheres
growing in defined media without EGF and FGF2 were treated for 24 h with GH or saline, and BrdU incorporation was detected as indicated.
Each bar represents the mean + SEM of 3 experiments in triplicate.
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neurosphere cultures, we treated them with U0126, a
highly specific inhibitor of MEK1/2 that effectively blocks
ERK phosphorylation. Blockade of Ras-ERK signaling not
only resulted in a prominent inhibition of neurosphere
proliferation (Figure 4A), but completely blocked the posi-
tive effect of GH on cell proliferation. Similarly, U0126
treatment induced a significant increase in the number of
apoptotic cells, although in this case, the effect was par-
tially counteracted by GH treatment (Figure 4B). Surpris-
ingly, and in contrast with previous reports [25,26], weFigure 3 GH treatment prevents apoptosis in SGZ neurospheres. A) N
without EGF and FGF2, and 24 h later treated with GH (500 ng/mL), pegvis
Control cells were treated with saline. Cell apoptosis was determined by TU
in triplicate. * = p <0.05 vs Control; ° = p <0.05 vs Control and p <0.01 vs GH
media (Control + EGF + FGF2). Apoptosis values in this group were significa
B) Representative images of results presented in A. Scale bar = 10 μm.have been unable to find any effect of GH on ERK phos-
phorylation in cultured SGZ neurospheres (Figures 4C
and D).
Role of the Phosphoinositide 3-kinase (PI-3 K)/Akt/mTOR
signaling pathway in the proliferative and antiapoptotic
effects of GH
The role of the PI-3 K/Akt/mTOR pathway in GH sig-
naling has been also supported by several previous ob-
servations [27,28]. Activation of GHR induces the
phosphorylation of the GHR-associated protein Insulineurospheres growing in defined media were placed in defined media
omant (20 μg/mL), or GH + pegvisomant for an additional 48 h period.
NEL staining. Each bar represents the mean + SEM of 3 experiments
. Basal apoptosis was determined by growing the cells in the defined
ntly lower (p <0.01) than in the other groups. E = EGF; F = FGF2.
Figure 4 ERK phosphorylation is necessary for neurosphere proliferation and survival. A) Neurospheres growing in defined media were
treated for 24 h with GH (500 ng/mL), U0126 (20 μM) or GH + U0126. Control cells were treated with saline. Four hours before the end of the
treatment period cells were given a BrdU pulse (10 μM). Neurospheres were then dissociated and cells were collected by centrifugation onto
coated cover slips, and BrdU was detected by immunocytochemistry. * = p <0.05 vs Control; ** = p < 0.001 vs control and GH. B) Neurospheres
were placed into culture plates containing defined media without EGF and FGF2, and 24 h later treated with GH, U0126 or GH + U0126, for an
additional 48 h period. Control cells were treated with saline. Cell apoptosis was determined by TUNEL staining. Each bar represents the mean +
SEM of 3 experiments in triplicate. * = p <0.01 vs Control; ** = p <0.001 vs control and GH; ° = p <0.01 vs GH. Basal apoptosis was determined by
growing the cells in the defined media (Control + EGF + FGF2). Apoptosis values in this group were significantly lower (p <0.01) than in the other
groups. E = EGF; F = FGF2. C) Neurospheres were deposited for 48 h in slides with defined media without EGF and FGF2, and then treated with
GH for 1 h. Phospho ERK and GAPDH immunoreactivities were determined by western blot. D) Densitometric evaluation of results presented in C.
Phospho ERK levels are expressed as arbitrary densitometric units and normalized to GAPDH levels.
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3 K that promotes Akt phosphorylation. In keeping
with those findings, GH treatment induced a prompt
and marked rise in phospho-Akt levels in SGZ-derived
neurospheres (Figures 5A and B). Once phosphorylated,
Akt activates the phosphoinositide-dependent kinase-1
(PDK1) that, in turns, phosphorylates a number of intra-
cellular targets including mTOR [28] which, reportedly,
plays a major role in the regulation of proliferation and
survival in different types of cells [29,30]. Therefore, in
order to assess the involvement of the PI-3 K/Akt/
mTOR pathway on GH actions, we first treated neuro-
sphere cultures with rapamycin, an inhibitor of the
mTOR complex 1 (mTORC1). As Figure 5C depicts,
treatment with rapamycin significantly reduced the
proliferation of neurosphere cultures, and completely
abolished the effect of GH. Interestingly rapamycin
also induced a significant increase in cell death but, in
this case, the effect was partially counteracted by GH
(Figure 5D). In order to further investigate the involve-
ment on Akt stimulation of this effect, cells were also
treated with LY294002, a potent inhibitor of PI-3 K. In
keeping with previous results in other cell types [27,31,32],inhibition of Akt phosphorylation significantly increased
the number of apoptotic cells (Figure 5E) while, as oc-
curred with rapamycin treatment, GH was able to partially
overcome this effect (Figure 5E).
GH-induced JNK phosphorylation is involved in the
antiapoptotic effects of GH
Finally, we investigated the role of JNK in mediating the
effects of GH on neurosphere proliferation and survival.
In keeping with previous findings in fibroblasts [31] or
macrophages [32], GH was able to induce the phosphor-
ylation of JNK in cultured neurospheres (Figures 6A and B).
When JNK actions were counteracted by treating the cells
with SP600125, a competitive inhibitor of its kinase activity,
both proliferation and survival were significantly decreased
in neurosphere cultures (Figures 6C and D). Interestingly,
none of these effects could be counteracted by GH
treatment.
Discussion
This study was designed to investigate the role of GH on
postnatal neurogenesis using a neurosphere culture system.
The presence of ongoing neurogenesis in the postnatal
Figure 5 The PI-3 K/Akt pathway is involved in the antiapoptotic affect of GH. A) Neurospheres were deposited for 48 h in slides with
defined media without EGF and FGF2, and then treated with GH for 1 h. Phospho Akt and GAPDH immunoreactivities were determined by
western blot. B) Densitometric evaluation of results presented in A. Phospho Akt levels are expressed as arbitrary densitometric units and
normalized to GAPDH levels. C) Neurospheres growing in defined media were treated for 24 h with saline (Control), GH (500 ng/mL), rapamycin
(20 nM), or GH + rapamycin. Four hours before the end of the treatment period cells were given a BrdU pulse (10 μM). Neurospheres were then
dissociated and cells were collected by centrifugation onto coated cover slips, and BrdU was detected by immunocytochemistry. * = p <0.05 vs
Control; ** = p <0.001 vs Control and GH. D) and E) Neurospheres were placed into culture plates containing defined media without EGF and
FGF2, and 24 h later treated for 48 h with saline, GH, rapamycin or GH + rapamycin, [D)] or saline, GH, LY 294002 (10 μM) or GH + LY 294002,
[E)]. * = p < 0.01 vs Control; ** = p <0.01 vs Control and p <0.001 vs GH; ° = p <0.01 vs GH. In D) and E) basal apoptosis, determined by growing
the cells in the defined media (Control +E+ F), was significantly lower (p <0.01) than in the other groups. E = EGF; F = FGF2. Bars = mean + SEM
of 3 experiments in triplicate.
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cell pools present in the adult brain can be directed to-
wards repair of neural injuries has generated much interest
for the last several years, see [19,33] for review. Further-
more, since postnatal neurogenesis is regulated by a com-
plex network of signaling molecules and extrinsic factors
[12], understanding these mechanisms of control will help
to find effective treatments directed towards increase
neurogenesis in order to promote brain repair.
GH has been proposed to play a role on brain repair
after injury [34]. Although some of the beneficial effects
of GH on brain repair may depend on their neuropro-
tective actions [33], there is also accumulating evidence
indicating that neurogenesis is also stimulated by GH.
Thus GH treatment has been demonstrated to promote
neurogenesis in different brain areas [20,23,24,35] either
under unperturbed conditions [20,35] or in response to
brain damage [23,24]. Interestingly, GH-induced neuro-
genesis is potentiated when GH treatment is combined
with physical exercise [35,36] or physical rehabilitation
[24], thus suggesting that the hormone is not only co-
operating with endogenous mechanisms regulating post-
natal neurogenesis, but may be even essential to induce
the neurogenic response [36]. There is also evidence
indicating that GH increases the frequency of bothrodent- and human-derived neurospheres in vitro [37-41;
and the present study], thus demonstrating a direct effect
of GH on neural precursor cells. Furthermore, in all these
cases, GH actions are lost when GHR is absent or inacti-
vated, thus indicating that GH actions are exerted via acti-
vation of GHR; although the possibility that some of GH
actions on neural precursors may depend on the activa-
tion of other receptors cannot be ruled out [41].
Once established the importance of GH in the regula-
tion of proliferation and survival of SGZ-derived neuro-
spheres, we next investigated the molecular mechanism
underlying these actions. The predominant GH signal
transduction cascade comprises activation of the GHR
dimer and phosphorylation of Janus kinase 2 (JAK2). Ac-
tivated JAK2 then phosphorylates key tyrosine residues
on the cytoplasmic domain of the GHR, permitting SH2
domain interactions by signal adaptor proteins that re-
sults in docking of signal transducer and activator of
transcription 5 (STAT5) for activation by JAK2 [25,26].
The triggering of this canonical signaling pathway has
been recently demonstrated in neurosphere cells [38],
and may be involved in some of the GH actions on these
cells. However, phosphorylation of the cytoplasmic do-
main of the GHR also results in the activation of the
Ras/MAPK kinase/ERK pathway; while activated JAK2 is
Figure 6 JNK phosphorylation is involved in the proliferative and antiapoptotic affects of GH. A) Neurospheres were deposited for 48 h
in slides with defined media without EGF and FGF2, and then treated with GH for 1 h. Phospho JNK and GAPDH immunoreactivities were
determined by western blot. B) Densitometric evaluation of results presented in A. Phospho JNK levels are expressed as arbitrary densitometric
units and normalized to GAPDH levels. C) Neurospheres growing in defined media were treated for 24 h with GH (500 ng/mL), SP600125 (20 μM)
or SP600125 + GH. Control cells were treated with saline. Four hours before the end of the treatment period cells were given a BrdU pulse
(10 μM). Neurospheres were then dissociated and cells were collected by centrifugation onto coated cover slips, and BrdU was detected by
immunocytochemistry. * = p <0.05 vs Control; ** = p <0.001 vs Control and GH. D) Neurospheres were placed into culture plates containing
defined media without EGF and FGF2, and 24 h later treated with GH, SP600125 or SP600125 + GH, for an additional 48 h period. Basal apoptosis
was determined by growing the cells in the defined media (Control + EGF + FGF2). Apoptosis values in this group were significantly lower (p <0.01)
than in the other groups. * = p <0.05 vs Control; ** = p <0.001 vs Control and GH. E = EGF; F = FGF2. Bars= mean + SEM of 3 experiments in triplicate.
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activation of the PI3K/Akt/mTOR pathway [25,26].
Our findings demonstrate that at least two of those
signaling pathways, the PI-3 K/Akt/mTOR and JNK
module of the MAPK, are activated by GH in cultured
neurospheres, thus illustrating the complexity of GHR
signaling in these cells. Furthermore, by using selective
inhibitors we have been able to demonstrate that, despite
these signaling pathways may be important in mediating
the GH effects on cell proliferation, they appear to exert
a more essential role in the regulation of cell survival.
There are several types of evidences supporting our hy-
pothesis. First, GH was able to partially overcome the ef-
fect of ERK inhibition on cell survival, while its effect oncell proliferation was completely abrogated under these
circumstances. The ability of GH to promote cell sur-
vival in the absence of ERK signaling indicates that GH
is able to deliver a survival signal that is independent on
Ras/ERK pathway activation. In contrast, Ras/ERK sig-
naling is necessary for the GH effect on neurosphere
proliferation indicating that, in keeping with previous re-
ports [41,42], GH is neither sufficient nor necessary for
neurosphere proliferation.
Second, GH treatment also partially counteracted the
negative effect of rapamycin on cell survival, but did not
modify rapamycin-induced inhibition of cell prolifera-
tion. Interestingly, mTOR has been shown to be relevant
for EGF-dependent proliferation of neural precursors
Devesa et al. BMC Neuroscience 2014, 15:100 Page 7 of 11
http://www.biomedcentral.com/1471-2202/15/100[43], further supporting our hypothesis regarding a
minor role of GH on the regulation of neurosphere pro-
liferation. Furthermore, mTOR is present in two distinct
complexes: mTOR complex 1 (mTORC1) and mTOR
complex 2 (mTORC2) [30,44]. Since only mTORC1 is
inhibited by rapamycin, the possibility exists that GH ac-
tions on cell survival may depend, at least in part, on the
rapamycin-insensitive mTORC2 complex, as occurs with
insulin [45]. Another possible mechanism, not excluding
the former, is that GH may overcome the effect of rapa-
mycin treatment via the stimulation of survival signals
that do not depend on the PI-3 K/Akt/mTOR pathway.
In this regard, it is interesting to indicate that the abil-
ity of GH to prevent apoptosis was preserved in the
presence of PI-3 K inhibition, thus suggesting that Akt
activation does not play a major anti-apoptotic role in
these cells.
In contrast with these findings, GH effects on both cell
proliferation and survival were completely inhibited
when the phosphorylation of JNK was blocked. JNKs are
members of the MAPK family that are activated by a
variety of environmental stresses, inflammatory cyto-
kines and, in some instances, by growth factors and
GPCR (G protein-coupled receptor) agonists [46]. Once
activated, the JNK pathway regulates numerous cellular
responses including cell proliferation and survival, to-
gether with different aspects of neural development
[47-50]. Therefore, the fact that blockade of JNK signal-
ing completely inhibited both the proliferation and sur-
vival of SVZ-derived neurospheres, indicates that this
pathway plays a major role in the regulation of the cellu-
lar fate of these cells. Furthermore, the fact that both
GH-induced proliferation and survival are also blocked
under these experimental conditions, together with the
ability of GH to promote JNK phosphorylation, indicates
that the JNK pathway is a key component of the signal-
ing machinery activated by GH in SVZ-derived neuro-
spheres. To our knowledge, this is the first time to
demonstrate the capacity of GH to induce the phosphor-
ylation of JNK in neural cells. To the present, GH-
induced JNK phosphorylation has been demonstrated in
macrophages [34], in NIH 3 T3 fibroblasts [33], and also
in chinese hamster ovary cells stably transfected with rat
GH receptor cDNA [51]. However, GH has been shown
to reduce both basal and doxorubicin-stimulated JNK
transcriptional activity and phosphorylation in both
MDA-MB-231 and MCF7 cells [52], thus demonstrating
the complexity of GH-mediated JNK regulation.
Finally, it is noteworthy to indicate that blockade of
GH signaling was able to induce a decrease in neuro-
sphere proliferation and survival even in cells not receiv-
ing GH treatment. This finding, together with the
existence of GH expression in cultured neurospheres
([41]; and the present report), suggests the existence ofan endogenous GH axis regulating the proliferation and
apoptosis of neural progenitors. Up to now, the exist-
ence of GH immunoreactivity has been reported in sev-
eral brain areas that include germinal regions of the
embryonic brain [53], as well as brain regions involved
in postnatal neurogenesis [54-56]. Furthermore, GH
gene expression within these areas is increased by fac-
tors known to increase neurogenesis such as learning,
exercise or estrogen administration (37; 54, 55), while
such increase is not observed in GHR-/- animals (37).
Altogether, these findings lead to the possibility that GH
treatment is, in fact, cooperating with locally-produced
GH in increasing the proliferation of neural progenitors
in response to adequate stimuli. In this regard, it is inter-
esting to note that we have previously found that GH is
expressed in rat hippocampal progenitors, and that GH
expression increases after neurotoxic damage (23).
Therefore, it is tempting to speculate that, this locally-
produced GH may cooperate with the exogenous hor-
mone in promoting neurogenesis and cell survival in
response to brain injury.
Conclusions
Altogether, these findings lead to the possibility that GH
treatment is, in fact, cooperating with locally-produced
GH in increasing the proliferation and survival of neural
progenitors in response to adequate stimuli. In this re-
gard, the fact that increased GH expression has been de-
tected in hippocampal progenitors after neurotoxic
damage [23] suggests that endogenous and exogenous
GH may also cooperate in promoting neurogenesis and
cell survival in response to brain injury.
Methods
SGZ cultures and treatments
All animal procedures were carried out in accordance
with European Union guidelines for the care and use of
laboratory animals and they were approved by the Ethics
committees of the Universities of Santiago de Compos-
tela and Coimbra. SGZ cells were obtained from 9-day-
old C57BL/6 donor mice as previously described [25].
Briefly, brains were removed under sterile conditions
and placed in calcium- and magnesium-free Hanks’
balanced salt solution (Life Technologies Corporation,
Carlsbad, CA). Sagittal brain sections (350 μm-thick)
prepared with a McIlwain tissue chopper were used to
dissect SGZ fragments. Fragments were then digested
in 0.025% trypsin (Life Technologies Corporation) and
0.265 mM EDTA (Life Technologies Corporation) for
10 minutes at 37°C, and gently dissociated with a 1000 mL
plastic pipette tip. The resulting cell suspension was diluted
in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 100 U/mL penicillin, 100 μg/mL strepto-
mycin, 1% Gibco B27 supplement, 10 ng/mL epidermal
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factor 2 (FGF2) (defined media; all from Life Technologies
Corporation). Cells were then plated on uncoated dishes
(Corning Incorporated, Corning, NY) at a density of 3,000
cells per cm2 and maintained at 37°C in a 5% CO2 atmos-
phere in order to allow neurosphere development. Ten to
12 days after plating, the SGZ-derived neurospheres were
collected and placed in fresh DMEM and used for cell pro-
liferation studies. In order to induce cell apoptosis, neuro-
sphere cells were placed in DMEM supplemented with 100
U/mL penicillin, 100 μg/mL streptomycin and 1% Gibco
B27 supplement. Further experimental details are provided
in the corresponding figure legend.
Recombinant human GH (Humatrope) was obtained
from Eli Lilly and Company (Madrid, Spain); pegviso-
mant (Somavert), an antagonist of GH receptor (GHR),
was obtained from Pfizer (Madrid, Spain); the extracellu-
lar signal-regulated kinase (ERK) inhibitor U0126, the
mammalian target of rapamycin (mTOR) inhibitor rapa-
mycin, and the c-Jun N-terminal kinase (JNK) inhibitor
SP600125 were purchased from Sigma-Aldrich (Madrid,
Spain). The PI-3 K inhibitor LY 294002 was purchased
from Promega (Madison, WI).
Immunofluorescence
After fixation in 4% PFA for 30 minutes at room
temperature, SGZ cells were permeabilized, and nonspe-
cific binding sites were blocked with 0.25% Triton X-100
and 3% BSA for 30 minutes at room temperature. SGZ
cells were then incubated overnight at 4°C with the fol-
lowing primary antibodies: polyclonal anti-GHR (Abcam,
Cambridge, MA; dilution 1:500), polyclonal anti-GH
(Abcam; dilution 1:200), monoclonal anti-glial fibrillary
acidic protein (GFAP) (Cell Signaling Technology, Dan-
vers, MA; dilution 1:500), monoclonal anti-nestin (EMD
Millipore Corporation, Billerica, MA; dilution 1:200),
monoclonal anti-O4 (EMD Millipore Corporation; dilu-
tion 1:200). Coverslips were then rinsed in PBS and
incubated for 1 hour at room temperature with the ap-
propriate secondary antibodies: anti-rabbit IgG labeled
with Alexa Fluor 488 (1:200) or with Alexa Fluor 594
(1:200), or anti-mouse IgG labeled with Alexa Fluor 594
(1:200) (all from Life Technologies). After an additional
rinse in PBS, cell nuclei were stained with Hoechst
33342 (Life Technologies, 2 μg/mL in PBS containing
0.25% BSA) for 5 minutes at room temperature. Finally,
the preparations were mounted using Dako-Cytomation
fluorescent medium (DakoCytomation, Carpinteria, CA).
Negative controls without primary antibody application
showed lack of specific immunoreactivity with minimum
background staining (data not shown). Fluorescent images
were recorded using a confocal microscope (LSM 510
Meta; Carl Zeiss, Gottingen, Germany) or an Axioskop 2
Plus fluorescent microscope (Carl Zeiss).Cell proliferation studies
To assess cell proliferation, neurosphere cells growing in
defined media received a treatment for 24 hours and were
exposed to 10 μM 5-bromo-2′-deoxyuridine (BrdU)
(Sigma-Aldrich) for the last 4 hours. Cultures were then
fixed in 4% PFA for 30 minutes and, after extensive rinsing
(30 minutes in 0.15 M PBS, at room temperature), BrdU
was unmasked by successive passages in: 1% Triton X-100
for 30 minutes at room temperature, ice-cold 0.1 M HCl
for 20 minutes, and 2 M HCl for 40 minutes at 40°C. Fol-
lowing neutralization in sodium borate buffer (0.1 M
Na2B4O7 · 10H2O, pH 8.5; Sigma-Aldrich) for 15 minutes
at room temperature, slices were rinsed in PBS, and non-
specific binding sites were blocked with 3% bovine serum
albumin (BSA; Sigma-Aldrich) and 0.3% Triton X-100 for
30 minutes at room temperature. SGZ cultures were then
incubated overnight at 4°C with a primary anti-BrdU anti-
body (EMD Millipore Corporation; dilution 1:50) in PBS
containing 0.1% Triton X-100 and 0.3% BSA. After rinsing
in PBS, cells were incubated with a secondary antibody la-
beled with Alexa Fluor 594 (Life Technologies, dilution
1:200) for 1 hour at room temperature. After an additional
rinse in PBS, cell nuclei were stained with Hoechst 33342
(Life Technologies, 2 μg/mL in PBS containing 0.25%
BSA) for 5 minutes at room temperature. Finally, the
preparations were mounted using DakoCytomation fluor-
escent medium (DakoCytomation). Fluorescent images
were recorded using a confocal microscope (LSM 510
Meta; Carl Zeiss) or an Axioskop 2 Plus fluorescent
microscope (Carl Zeiss). For each well, 8 random fields
were photographed and BrdU + cells were scored.
Cell survival studies
Cell apoptosis was evaluated by terminal deoxy-
nucleotidyl transferase dUTP nick-end labeling (TUNEL),
as previously described [57]. Briefly, permeabilized cells
were incubated in terminal deoxy-nucleotidyl transferase
buffer (0.25 U/μl terminal transferase, 6 μM biotinylated
dUTP, pH 7.5; all from Roche Farma, S.A, Madrid, Spain)
for 1 hour 30 minutes at 37°C in a humidified chamber.
The enzymatic reaction was stopped by 15 minutes of in-
cubation in 300 mM NaCl (Sigma-Aldrich) and 30 mM
sodium citrate buffer (Sigma-Aldrich). Following an add-
itional rinse in PBS, cultures were incubated for 30 minutes
at room temperature with the avidin-biotin-peroxidase
complex (1:100; Vector Laboratories, Burlingame, CA).
Peroxidase activity was revealed by the 3,3′-diaminobenzi-
dine chromogen (0.025%; Sigma-Aldrich) intensified with
0.08% NiCl2 in 30 mM Tris-HCl (pH 7.6) buffer contain-
ing 0.003% H2O2. The cell preparations were then dehy-
drated in ethanol (70%, 2 minutes; 80%, 2 minutes; 90%,
2 minutes; 95%, 2 minutes; 100%, 2 minutes), cleared in
xylene (3 minutes), and mounted using DEPEX mounting
medium (Sigma-Aldrich). Photomicrographs of TUNEL
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Zeiss) adapted to an Axioskop 2 Plus fluorescent micro-
scope (Carl Zeiss). For each well, 8 random fields were
photographed and positive cells were scored.
Western blot
For phospho-ERK, phospho-Akt and phospho-JNK de-
termination, neurospheres were maintained for 12-13
days in DMEM supplemented with 100 U/mL penicillin,
100 μg/mL streptomycin, 1% Gibco B27 supplement,
EGF (10 ng/mL), and FGF2 (10 ng/mL); and then placed
in plates containing DMEM supplemented with 100 U/mL
penicillin, 100 μg/mL streptomycin and 1% Gibco B27 sup-
plement for 12 h. Finally, the medium was replaced with
fresh DMEM supplemented with 100 U/mL penicillin,
100 μg/mL streptomycin and 0.1% Gibco B27 supplement,
and incubated for an additional 12 h period. Cells were
then collected by centrifugation and the pellet was then
lysated by heating at 95°C for 5 min in 1% SDS, and imme-
diately cooled at 4°C for 15 min with ice-cold lysis buffer
(50 mM Hepes, pH 7.5; 150 mM NaCl; 10% glycerol; 1%
triton X-100; 5 mM EGTA; 1.5 mM MgCl2; 20 mM
Na4P2O7; 20 mM Na3VO4; 50 μg/mL aprotinin and 4 mM
phenylmethylsulfonyl fluoride). After centrifugation (15,000 g,
15 min, 4°C) to separate cellular debris, the lysates were
resolved in a 12% SDS-PAGE, and electrotransferred onto
nitrocellulose paper (Protran; Schleicher and Schuell,
Dassel, Germany). Primary antibodies rose against pAkt,
pERK, pJNK and glyceraldehyde 3-phosphate dehydrogen-
ase (GAPDH) (all from Cell Signaling, dilution 1:1000),
were applied overnight at 4°C, and were detected using
alkaline phosphatase-conjugated secondary antibodies (di-
lution 1:20000). Immunoreactive bands were detected
with a western-light chemiluminescence detection system
(ECL; APBiotech, Little Chalfont, UK) and photographed
(HyperfilmECL; APBiotech). Immunoreactive bands were
scanned with a GelDoc system (Bio-Rad, Hercules, Calif.,
USA) and optical density was determined with the ImageJ
software (National Institutes of Health, Bethesda, MD, USA).
Statistics
Statistical analysis was performed with the non-parametric
Mann–Whitney test. Statistical significance was established
at P < 0.05.
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